Fennec Pharmaceuticals
FENC | NASDAQ
$12.76
+$1.14 (+9.81%)
At close: Nov 16, 2026, 4:00 PM ET
$12.70
-$0.06 (-0.47%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+9.81%
(1D)No price chart data available for 1D timeframe.
Rating
60.8
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #129/1021 (Top 13%)
Key Statistics
Market Data
Market Cap $450.49M
1D Range
11.82 12.88
52W Range
5.77 12.88
Valuation (TTM)
PE 2.28K
PB 9.16
EV/EBITDA 151.74
Valuation (NTM)
Forward PE 35.21
Forward PEG -1.44
Price Target $16.00
Cash Flow
FCF Yield 0.7%
SBC Adj. FCF Yield -0.6%
SBC Impact -179.4%
Margins
Gross Margin 94.1%
Operating Margin 5.6%
FCF Margin 4.7%
Growth (CAGR)
Revenue 3Y | 5Y 72.0% |
229.8%
Dil EPS 3Y | 5Y 47.4% |
56.3%
FCF 3Y | 5Y -163.5% |
156.5%
Returns
ROA 2.4%
ROE 4.9%
ROIC 4.3%
Financial Health
Net Cash
$48.68M
Current Ratio 6.11
Interest Coverage 11.57
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment i...
Sector Healthcare
Industry Biotechnology
Employees 35
IPO Date Sep 15, 2017
Website www.fennecpharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
$0.12
Beat +25.00%
YoY:
+700.00% REV
$19.61M
Beat +3.92%
YoY:
+57.34%Next Earnings
Mar 23, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$16.00
Upside
+25.39%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove FENC